Heart & Lung: The Journal of Acute and Critical Care
Volume 38, Issue 1 , Pages 10-16 , January 2009

Increased N-terminal-pro-B-type natriuretic peptide levels in patients with appropriate implantable defibrillator therapies

  • Fabian J. Arnaldo, MD

      Affiliations

    • University of Florida College of Medicine-Jacksonville, Department of Medicine, Jacksonville, Florida
    • Corresponding Author InformationCorresponding author: Fabian J. Arnaldo, MD, 1461 Majesty Terrace, Weston, FL 33327
    • ,
  • Nikolaos Anatoliotakis, MD

      Affiliations

    • University of Florida College of Medicine-Jacksonville, Department of Medicine, Jacksonville, Florida
    • ,
  • Carlos Palacio, MD

      Affiliations

    • University of Florida College of Medicine-Jacksonville, Department of Medicine, Jacksonville, Florida
    • ,
  • David R. Nabert, MD

      Affiliations

    • Cardiology Division, Cardiac Electrophysiology, Jacksonville, Florida
    • ,
  • Steve S. Hsu, MD

      Affiliations

    • Cardiology Division, Cardiac Electrophysiology, Jacksonville, Florida

References 

  1. Cowie MR, Struthers AD, Wood DA, et al. Value of natriuretic peptides in the assessment of patients with possible new heart failure in primary care. Lancet. 1997;350:1349–1353
  2. Klogin J, Pehlivanli S, Schwaiblmair M, Vogeser M, Cremer P, von Scheidt W. Role of brain natriuretic peptide in risk stratification of patients with congestive heart failure. J Am Coll Cardiol. 2001;38:1934–1941
  3. Wright SP, Doughty RN, Pearl A, et al. Plasma amino-terminal pro-brain natriuretic peptide and accuracy of heart failure diagnosis in primary care. J Am Coll Cardiol. 2003;42:1793–1800
  4. Silver MA, Maisel A, Yancy CW, et al. BNP Consensus Panel BNP consensus panel 2004: A clinical approach for the diagnostic, prognostic, screening, treatment monitoring and therapeutic roles of natriuretic peptides in cardiovascular diseases. Congest Heart Fail. 2004;10(5 suppl 3):1–30
  5. Rodeheffer RJ. Measuring plasma B-type natriuretic peptide in heart failure (Good to go in 2004?). J Am Coll Cardiol. 2004;44:740–749
  6. de Lemos JA, Morrow DA, Bentley JH, et al. The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med. 2001;345:1014–1021
  7. Morrow DA, de Lemos JA, Sabatine MS, et al. Evaluation of B-type natriuretic peptide for risk assessment in unstable angina/non-ST elevation myocardial infarction: B-type natriuretic peptide and prognosis in TACTICS-TIMI 18. J Am Coll Cardiol. 2003;41:1264–1272
  8. Berger R, Huelsman M, Strecker K, et al. B-type natriuretic peptide predicts sudden death in patients with chronic heart failure. Circulation. 2002;105:2392–2397
  9. Rankovic V, Karha J, Passman R, Kadish AH, Goldberger JJ. Predictors of appropriate implantable cardioverter-defibrillator therapy in patients with idiopathic dilated cardiomyopathy. Am J Cardiol. 2002;89:1072–1076
  10. Whang W, Mittleman MA, Rich DQ, et al. Heart failure and risk of shocks in patients with implantable cardioverter-defibrillators: results of the Triggers Of Ventricular Arrhythmias (TOVA) study. Circulation. 2004;109:1386–1391
  11. Gillis A, Sheldon R, Wyse G, Duff H, Cassidy M, Mitchell LB. Clinical and electrophysiologic predictors of ventricular tachycardia recurrence in patients with implantable cardioverter defibrillators. J Cardiovasc Electrophysiol. 2003;14:492–498
  12. Verma A, Kilicaslan F, Martin DO, et al. Pre-implantation B-type natriuretic peptide level is an independent predictor of future appropriate implantable defibrillator therapies. Heart. 2006;92:147–148
  13. Manios EG, Kallergis EM, Kanoupakis EM, et al. Amino-terminal pro-brain natriuretic peptide predicts ventricular arrhythmogenesis in patients with ischemic cardiomyopathy and implantable cardioverter-defibrillators. CHEST. 2005;128:2604–2610
  14. Klingenberg R, Zugck C, Becker R, et al. Raised B-type natriuretic peptide predicts implantable cardioverter-defibrillator therapy in patients with ischaemic cardiomyopathy. Heart. 2006;92:1323–1324
  15. Moss AJ, Hall WJ, Cannom DS, et al. The Multicenter Automatic Defibrillator Implantation Trial Investigators Improved survival with an implanted defibrillator in patients with coronary artery disease at high risk for ventricular arrhythmia. N Engl J Med. 1996;335:1933–1940
  16. Moss AJ, Zareba W, Hall WJ, et al. The Multicenter Automatic Defibrillator Implantation Trial II Investigators Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. 2002;346:877-33
  17. Buxton AE, Lee KL, Fisher JD, Josephson ME, Prystowsky EN, Hafley G. A randomized study of the prevention of sudden death in patients with coronary artery disease. N Engl J Med. 1999;341:1882–1890
  18. The Antiarrhythmic Versus Implantable Defibrillator (AVID) Investigators. a comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. N Engl J Med. 1997;337:1576–1583
  19. Bardy GH, Lee KL, Mark DB, et al. Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) Investigators Amiodarone or implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005;352:225–237
  20. Anwaruddin S, Lloyd-Jones DM, Baggish A, et al. Renal function, congestive heart failure, and amino-terminal pro-brain natriuretic peptide measurement: results from the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) Study. J Am Coll Cardiol. 2006;347:91–97
  21. Sweeney MO, Wathen MS, Volosin K, et al. Appropriate and inappropriate ventricular therapies, quality of life and mortality among primary and secondary prevention implantable cardioverter-defibrillator patients (Results from the pacing fast VT reduces shock therapies (PainFree Rx II) trial). Circulation. 2005;111:2898–2905
  22. Wathen MS, Sweeney MO, DeGroot PJ, et al. PainFree Rx Investigators Shock reduction using antitachycardia pacing for spontaneous rapid ventricular tachycardia in patients with coronary artery disease. Circulation. 2001;104:796–801
  23. Hansen DE, Craig CS, Hondeghem LM. Stretch-induced arrhythmias in isolated canine ventricle (Evidence for the importance of mechanoelectrical feedback). Circulation. 1990;81:1094–1105
  24. Riemer TL, Sobie EA, Tung L. Stretch-induced changes in arrhythmogenesis and excitability in experimentally based heart cell models. Am J Physiol. 1998;275:H431–H442
  25. Pye MP, Cobbe SM. Arrhythmogenesis in experimental models of heart failure: the role of increased load. Cardiovasc Res. 1996;32:248–257
  26. Erol-Yilmaz A, Verberne HJ, Schrama TA, et al. Cardiac resynchronization induces favorable neurohormonal changes. PACE. 2005;28:304–310

PII: S0147-9563(07)00236-1

doi: 10.1016/j.hrtlng.2007.12.005

Heart & Lung: The Journal of Acute and Critical Care
Volume 38, Issue 1 , Pages 10-16 , January 2009

Article Tools

* Image Usage & Resolution